These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22860637)

  • 1. Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial.
    Stalmans I; Callanan DG; Dirks MS; Moster MR; Robin AL; Van Calster J; Scheib SA; Dickerson JE; Landry TA; Bergamini MV
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):559-65. PubMed ID: 22860637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma.
    Robin AL; Suan EP; Sjaarda RN; Callanan DG; Defaller J;
    Arch Ophthalmol; 2009 Feb; 127(2):173-8. PubMed ID: 19204235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma.
    Prata TS; Tavares IM; Mello PA; Tamura C; Lima VC; Belfort R
    J Glaucoma; 2010 Sep; 19(7):488-92. PubMed ID: 20051887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.
    Robin AL; Clark AF; Covert DW; Krueger S; Bergamini MV; Landry TA; Dickerson JE; Scheib SA; Realini T; Defaller JM; Cagle GD
    Am J Ophthalmol; 2009 Jan; 147(1):45-50.e2. PubMed ID: 18789793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration.
    Augustin AJ; D'Amico DJ; Mieler WF; Schneebaum C; Beasley C
    Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):9-12. PubMed ID: 15290154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
    Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
    Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial.
    Weinreb RN; Bacharach J; Fechtner RD; Kahook MY; Wirta D; Burmaster S; Meng X; Hubatsch DA
    Ophthalmology; 2019 Aug; 126(8):1095-1104. PubMed ID: 30403988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study.
    Moss EB; Buys YM; Low SA; Yuen D; Jin YP; Chapman KR; Trope GE
    J Glaucoma; 2017 Feb; 26(2):182-186. PubMed ID: 27096722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.
    Brandt JD; VanDenburgh AM; Chen K; Whitcup SM;
    Ophthalmology; 2001 Jun; 108(6):1023-31; discussion 1032. PubMed ID: 11382623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
    Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
    Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
    Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
    Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
    Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P;
    Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
    Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
    Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
    Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
    Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.